Paola Queirolo - Concepedia

Author

Paola Queirolo

Also Known As

Alfredo Falcone, Avinash Aujayeb, Francesca Mazzoni, Francesco Spagnolo, Giovanna Bianchi-Scarrà, Mario Mandalà, Mario P. Colombo, Maristella Saponara, P QUEIROLO, P Queirolo

596

Publications

18.5K

Citations

H-Index

Concepts

All Affiliations

Ospedale Policlinico San Martino European Institute of Oncology Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"Istituti di Ricovero e Cura a Carattere Scientifico University of Genoa

About

Paola Queirolo is an author at Ospedale Policlinico San Martino specializing in medicine, oncology, and radiation oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	36	80	7.3K
2	Health Sciences	10	10	521
3	Engineering	1	1	11
4	Public Health	1	1	47
5	Biostatistics	1	1	19

Paola Queirolo

150

Publications

14.5K

Citations

H-Index

Page 1

	Year	Citations
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma Jeffrey S. Weber, Mario Mandalà, Michele Del Vecchio, New England Journal of Medicine	2017	2.1K
MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study Paolo A. Ascierto, Dirk Schadendorf, Carola Berking, The Lancet Oncology Tumor BiologyOpen-label Phase 2MedicineMelanomaPathology	2013	638
Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study Steven O’Day, Michele Maio, Vanna Chiarion‐Sileni, Annals of Oncology Pretreated Advanced MelanomaMedicineMelanomaClinical TrialsIpilimumab Monotherapy	2010	510
Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial Paolo A. Ascierto, Michele Del Vecchio, Mario Mandalà, The Lancet Oncology Checkmate 238Surgical OncologyMedicineMelanomaPathology	2020	505
Binimetinib versus dacarbazine in patients with advanced NRAS-mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial Reinhard Dummer, Dirk Schadendorf, Paolo A. Ascierto, The Lancet Oncology OncologyBinimetinib Versus DacarbazineMedicineMelanomaPharmacotherapy	2017	482
Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab Pier Francesco Ferrucci, Paolo A. Ascierto, Jacopo Pigozzo, Annals of Oncology	2016	389
Vaccination of Metastatic Melanoma Patients With Autologous Tumor-Derived Heat Shock Protein gp96-Peptide Complexes: Clinical and Immunologic Findings Filiberto Belli, Alessandro Testori, Licia Rivoltini, Journal of Clinical Oncology	2002	385
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial Alexander Eggermont, Christian U. Blank, Mario Mandalà, The Lancet Oncology Surgical OncologyMedicineMelanomaImmunologyImmune Checkpoint Inhibitor	2021	364
Final, 10-Year Outcomes with Nivolumab plus Ipilimumab in Advanced Melanoma Jedd D. Wolchok, Vanna Chiarion‐Sileni, Piotr Rutkowski, New England Journal of Medicine	2024	343
Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma Paolo A. Ascierto, Pier Francesco Ferrucci, Rosalie Fisher, Nature Medicine MedicineMelanomaImmune Checkpoint InhibitorOncologyRadiation Oncology	2019	319

Page 1